5LFY

Zinc bound dimer of the fragment of human amyloid-beta peptide with Alzheimer's disease pathogenic Taiwanese mutation D7H

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D DQF-COSY	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	90% H2O/10% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
2	2D 1H-1H TOCSY	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	90% H2O/10% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
3	2D 1H-1H NOESY	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	90% H2O/10% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
11	2D 1H-1H NOESY	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	100% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
4	2D 1H-15N HSQC	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	90% H2O/10% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
5	2D 1H-13C HSQC aliphatic	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	90% H2O/10% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
6	2D 1H-13C HSQC aromatic	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	90% H2O/10% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
7	2D 1H-13C HSQC aliphatic	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	100% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
8	2D 1H-1H ROESY	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	100% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
9	2D DQF-COSY	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	100% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
10	2D DOSY	1.4 mM D7H_Abeta(1-10), 2.8 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	100% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
12	2D 1H-15N HMBC	0.8 mM D7H_Abeta(1-10), 0.8 mM [U-99% 13C,15N]-(D1,3); [U-99% 15N]-(H6,H7) D7H_Abeta(1-10), 1.7 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	100% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
13	2D 13C-edited,13C-filtered NOESY	0.8 mM D7H_Abeta(1-10), 0.8 mM [U-99% 13C,15N]-(D1,3); [U-99% 15N]-(H6,H7) D7H_Abeta(1-10), 1.7 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	100% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600
14	2D 1H-15N HMBC-NOESY	0.8 mM D7H_Abeta(1-10), 0.8 mM [U-99% 13C,15N]-(D1,3); [U-99% 15N]-(H6,H7) D7H_Abeta(1-10), 1.7 mM ZnCl2, 10 mM [U-99% 2D] bis-Tris-d19	100% D2O	3 mM	7.0	1 atm	278	Bruker AVANCE 600

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	600

NMR Refinement
Method	Details	Software
simulated annealing		CNS

NMR Ensemble Information
Conformer Selection Criteria	structures with the least restraint violations
Conformers Calculated Total Number	50
Conformers Submitted Total Number	20
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	TopSpin		Bruker Biospin
2	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
3	data analysis	Sparky		Goddard
6	data analysis	Anglesearch		Polshakov
4	structure calculation	CNS		Brunger, Adams, Clore, Gros, Nilges and Read
5	data analysis	PROCHECK / PROCHECK-NMR		Laskowski and MacArthur

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.